TELA Bio plans public offering of common stock and pre-funded warrants

From GlobeNewswire: 2024-10-22 16:05:00

TELA Bio, Inc. announced a public offering of common stock and pre-funded warrants, with underwriters possibly buying an additional 15% of securities. The net proceeds will go towards general corporate purposes, such as sales, marketing, research, and development. The offering is subject to SEC regulations and being handled by Canaccord Genuity and Lake Street Capital Markets. TELA focuses on innovative soft-tissue reconstruction solutions that prioritize patient anatomy preservation and natural healing responses over permanent synthetic materials. Forward-looking statements caution about uncertainties and risks related to market conditions and the offering.



Read more at GlobeNewswire: TELA Bio Announces Proposed Public Offering of Common Stock